These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 29357824)
1. A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report. Verschoor AJ; Warmerdam FARM; Bosse T; Bovée JVMG; Gelderblom H BMC Cancer; 2018 Jan; 18(1):92. PubMed ID: 29357824 [TBL] [Abstract][Full Text] [Related]
2. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study. Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174 [TBL] [Abstract][Full Text] [Related]
6. Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes. Henriksen JN; Bøttger P; Hermansen CK; Ladefoged SA; Nissen PH; Hamilton-Dutoit S; Fink TL; Donskov F Clin Genitourin Cancer; 2020 Feb; 18(1):62-68.e2. PubMed ID: 31640912 [TBL] [Abstract][Full Text] [Related]
7. Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Leunen M; Breugelmans M; De Sutter P; Bourgain C; Amy JJ Gynecol Oncol; 2004 Dec; 95(3):769-71. PubMed ID: 15582003 [TBL] [Abstract][Full Text] [Related]
8. Long-term multidisciplinary treatment including proton therapy for a recurrent low-grade endometrial stromal sarcoma and pathologically prominent epithelial differentiation: an autopsy case report. Maeda O; Nagasaka T; Ito M; Mitsuishi T; Murakami F; Uematsu T; Hattori Y; Iwata H; Ogino H BMC Womens Health; 2020 Jul; 20(1):154. PubMed ID: 32711524 [TBL] [Abstract][Full Text] [Related]
9. Pazopanib efficacy and toxicity in a metastatic sarcoma cohort: Are Indian patients different? Sharma A; Vanidassane I; Aggarwal A; Mridha AR; Pandey R; Dhamija E; Barwad A; Rastogi S Indian J Cancer; 2019; 56(3):207-210. PubMed ID: 31389382 [TBL] [Abstract][Full Text] [Related]
10. Promising management of pazopanib-induced liver toxicity. Vlenterie M; van Erp NP; van der Graaf WT Acta Oncol; 2015 Jul; 54(7):1064-6. PubMed ID: 25734660 [No Abstract] [Full Text] [Related]
11. Pazopanib does not bring remarkable improvement in patients with angiosarcoma. Kitamura S; Yanagi T; Inamura Y; Hata H; Imafuku K; Yoshino K; Shimizu H J Dermatol; 2017 Jan; 44(1):64-67. PubMed ID: 27569550 [TBL] [Abstract][Full Text] [Related]
12. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature. Deguchi S; Mitsuya K; Nakasu Y; Hayashi N; Katagiri H; Murata H; Wasa J; Takahashi M; Endo M Invest New Drugs; 2018 Apr; 36(2):346-349. PubMed ID: 29067537 [TBL] [Abstract][Full Text] [Related]
13. Harnessing soft tissue sarcoma with low-dose pazopanib - a matter of blood levels. Groenland SL; Katz D; Huitema ADR; Steeghs N BMC Cancer; 2018 Dec; 18(1):1200. PubMed ID: 30509247 [TBL] [Abstract][Full Text] [Related]
14. Pazopanib and pancreatic toxicity: a case report. Russano M; Vincenzi B; Venditti O; D'Onofrio L; Ratta R; Guida FM; Tonini G; Santini D BMC Res Notes; 2015 May; 8():196. PubMed ID: 25967382 [TBL] [Abstract][Full Text] [Related]
15. Long-term survival in low-grade endometrial stromal sarcoma with childbirth and multidisciplinary treatment: a case report. Maeda O; Moritani S; Ichihara S; Inoue T; Ishihara Y; Yamamoto S; Ito M; Matsumura Y; Sugiyama K; Horio M; Kondo I J Med Case Rep; 2015 Oct; 9():233. PubMed ID: 26481040 [TBL] [Abstract][Full Text] [Related]
16. Aggressive behavior and poor prognosis of endometrial stromal sarcomas with YWHAE-FAM22 rearrangement indicate the clinical importance to recognize this subset. Kruse AJ; Croce S; Kruitwagen RF; Riedl RG; Slangen BF; Van Gorp T; Van de Vijver KK Int J Gynecol Cancer; 2014 Nov; 24(9):1616-22. PubMed ID: 25244606 [TBL] [Abstract][Full Text] [Related]
17. Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report. Alkasi O; Meinhold-Heerlein I; Zaki R; Fasching P; Maass N; Jonat W; Beckmann MW Arch Gynecol Obstet; 2009 Jan; 279(1):57-60. PubMed ID: 18379806 [TBL] [Abstract][Full Text] [Related]
18. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Lee CH; Ou WB; Mariño-Enriquez A; Zhu M; Mayeda M; Wang Y; Guo X; Brunner AL; Amant F; French CA; West RB; McAlpine JN; Gilks CB; Yaffe MB; Prentice LM; McPherson A; Jones SJ; Marra MA; Shah SP; van de Rijn M; Huntsman DG; Dal Cin P; Debiec-Rychter M; Nucci MR; Fletcher JA Proc Natl Acad Sci U S A; 2012 Jan; 109(3):929-34. PubMed ID: 22223660 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. Yoo KH; Kim HS; Lee SJ; Park SH; Kim SJ; Kim SH; La Choi Y; Shin KH; Cho YJ; Lee J; Rha SY BMC Cancer; 2015 Mar; 15():154. PubMed ID: 25885855 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study. Sunar V; Korkmaz V; Akin S; Can Guven D; Arik Z; Ates O; Yilmaz M; Mutlu Meydanli M; Oksuzoglu B J BUON; 2019; 24(6):2327-2332. PubMed ID: 31983102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]